Skip to main navigation Skip to search Skip to main content

The cost-effectiveness of using vilobelimab with immunomodulators to treat severely ill mechanically ventilated patients with COVID-19: A subgroup analysis of the PANAMO study

  • Daniel C. Malone
  • , Roger Seheult
  • , Diana Brixner
  • , Gary Oderda
  • , Bruce P. Burnett
  • , Joseph Biskupiak

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)e126-e133
JournalAmerican Journal of Health-System Pharmacy
Volume83
Issue number3
DOIs
StatePublished - Feb 1 2026

ASJC Scopus Subject Areas

  • Pharmacy
  • Pharmacology
  • Health Policy

Keywords

  • cost effectiveness
  • COVID-19
  • immunomodulators
  • quality-adjusted life years
  • vilobelimab

Cite this